Nebulised Heparin in Patients With Severe COVID-19
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19
Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective collaborative
individual patient data analysis of randomised controlled trials and early phase studies.
Individual studies are being conducted in multiple countries, including Australia, Ireland,
the USA, and the UK.
Mechanically ventilated patients with confirmed or strongly suspected SARS-CoV-2 infection,
hypoxaemia and an acute pulmonary opacity in at least one lung quadrant on chest X-ray, will
be randomised to nebulised heparin 25,000 Units every 6 hours or standard care (open label
studies) or placebo (blinded placebo controlled studies) for up to 10 days while mechanically
ventilated. All trials will collect a minimum core dataset. The primary outcome for the
meta-trial is ventilator-free days during the first 28 days, defined as being alive and free
from mechanical ventilation. Individual studies may have additional outcomes.